AstraZeneca takes latest scientific advances in oncology to major US and European congresses
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, will continue the oncology momentum built during 2016 with a strong end-of-year presence at three major congresses. In total, 50 abstracts - including 15 oral presentations - have been accepted across:
GSK Announces EU Regulatory Submission of Candidate Vaccine for Prevention of Shingles
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) has announced the regulatory submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for its candidate shingles vaccine, ShingrixTM, for the prevention of herpes zoster (shingles) in people aged 50 years or over.
Lilly announces top-line results of solanezumab phase 3 clinical trial
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
Shire to establish rare disease innovation hub in Cambridge, Mass.
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPG) has announced that it will expand its operations in Cambridge, Massachusetts, establishing a rare disease innovation hub and increasing its footprint in the heart of Kendall Square. Shire and BioMed Realty have signed a lease for a 343,000-square-foot building at 500 Kendall Street. Shire’s lease begins in Q3, 2018, with occupancy anticipated for Q1, 2019.
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
- Details
- Category: Novartis
Novartis today announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD).
Roche launches imCORE, a global network of cancer immunotherapy centers of excellence
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has launched the global cancer immunotherapy Centers of Research Excellence (imCORE™) Network. This network brings together many of the world's leading scientific and clinical experts in cancer immunotherapy to collaborate in investigating the most promising new treatment approaches.
Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study
- Details
- Category: Novartis
Novartis today announced positive topline results from the global Phase III STRIVE study, evaluating the efficacy and safety of the fully human monoclonal antibody AMG 334 (erenumab) in episodic migraine prevention. Once-monthly subcutaneous AMG 334 was evaluated at 70mg and 140mg doses, with both doses meeting the study's primary endpoint, demonstrating a statistically significant reduction from baseline in mean monthly migraine days at six months versus placebo.
More Pharma News ...
- Novo Nordisk expands programme to reach 20,000 children with diabetes in developing countries
- Merck wins R&D 100 Award for top invention
- Regorafenib from Bayer submitted to health authorities seeking approval in second-line treatment of liver cancer
- New European study highlights differing priorities in physician's therapy goals when treating advanced lung cancer patients
- Merck invests € 250 million in production value chain in China
- New study showed that only 55% of people with obesity have received a formal obesity diagnosis
- Pfizer's Prevenar 13® receives approval for use in infants and children in China